Abstract This study was conducted to determine whether circulating levels of lipoprotein (a), an independent risk factor of macrovascular disease, are increased in non-insulin-dependent diabetes mellitus (NIDDM) patients with microalbuminuria who have an increased risk of cardiovascular mortality. Apolipoprotein (a) [apo(a)] levels and phenotypes, and other circulating lipid levels were determined in 227 Chinese NIDDM patients with varying stages of diabetic nephropathy. None was on lipid-lowering therapy. Apo(a) levels in normoalbuminuric (geometric mean 166 U/L; 95% confidence intervals 137, 200; n= 105) and microalbuminuric patients (162; 132, 209; « = 77) were similar to values in controls (166; 143, 193, n=168). Albuminuric patients, however, had higher apo(a) levels than both normoalbuminuric patients and controls (242; 184, 317; n=45; P<0.05). The overall size range of the apo(a) phenotypes and the frequency of having at least one small isoform, i.e. < 700 kDa, were similar among the four groups of subjects. A positive correlation was found between log apo(a) and log plasma creatinine levels (/ > <0.01). Compared to normoalbuminuric patients, both microalbuminuric and albuminuric patients were older (P<0.0\) and had higher HbAlc (P<0.01), greater BMI (P<0.05) and longer disease duration (P<0.05) compared to normoalbuminuric patients. Nevertheless, using multiple linear regression analysis, it was found that the presence of nephropathy conferred an independent influence on increasing total cholesterol (P< 0.001), triglyceride (/>< 0.001) and apoB (/><0.01), and decreasing HDL cholesterol (P<0.05) levels even when only the normoalbuminuric and microalbuminuric groups were analysed. The prevalence of macrovascular disease was significantly increased in microalbuminuric and albuminuric patients (45.1 and 48.7% respectively vs 20.2% in normoalbuminuric patients, P<0.0\). It is concluded that circulating apo(a) levels were not increased in Chinese NIDDM patients with microalbuminuria. However, atherogenic changes in other lipid and lipoprotein levels may contribute to an increased risk of macrovascular disease in these patients.
Introduction
Lipoprotein (a) [Lp(a)] is a circulating macromolecular complex consisting of a glycoprotein apolipoprotein (a) [apo(a)], which shows structural similarity to plasminogen [1] , covalently linked to apolipoprotein B (apoB) of low density lipoproteins (LDLs). It has atherogenic and in vitro antifibrinolytic properties and has been recognized as an independent risk factor for premature atherosclerosis [2] . Because the risk of cardiovascular disease is increased in patients with diabetes and is further enhanced in the presence of microalbuminuria [3, 4] , various studies have been conducted to investigate the changes in Lp(a) levels in diabetic patients with or without microalbuminuria. In insulin-dependent diabetes mellitus (IDDM) [5] , Lp(a) levels are elevated and probably related to metabolic control and are further increased with microalbuminuria [6] . The contribution of elevated Lp(a) concentrations to enhanced atherogenesis in non-insulin-dependent diabetes mellitus (NIDDM) patients with microalbuminuria is less certain [5] . A significant increase in serum apo(a) levels was found in 26 microalbuminuric NIDDM patients by a group in Australia [7] . Lp(a) levels also tended to be higher in a Spanish study involving 11 NIDDM patients with microalbuminuria [8] , although the difference from those with normoalbuminuria was not statistically significant. However, recent studies conducted in Japan [9] and North America [10] have failed to confirm such findings, and the association between high Lp(a) levels and coronary heart disease, present in normoalbuminuric NIDDM patients, could not be demonstrated in the presence of diabetic nephropathy [11] . On the other hand, Lp(a) levels are usually reported to be increased in albuminuric NIDDM patients [5, 7] , although normal levels in both microalbuminuric and albuminuric patients have been reported from two studies [12, 13] .
The distribution of Lp(a) levels in the general population is highly skewed, with an extremely large range which is apo(a) isoform dependent [14] . Therefore, unless a large sample size is studied, a random deviation of certain apo(a) phenotypes can result in false positive or false negative differences between two or more groups of subjects. Differences in sample size may account for the discrepancies in Lp(a) levels reported by different studies on NIDDM patients with microalbuminuria. Except for the Santonio Valley Study [10] , the sample sizes involved were quite small in most of the reported studies [7] [8] [9] [12] [13] and apo(a) phenotypes were not assessed in any of the previous studies. In this study, we attempted to resolve the controversy regarding circulating Lp(a) levels in NIDDM patients with microalbuminuria by measuring both plasma apo(a) levels [which reflect the level of Lp(a)] and apo(a) phenotypes in a relatively large number of control subjects and NIDDM patients with or without microalbuminuria or albuminuria. Changes in other circulating lipid levels were also measured.
Subjects and methods
Two hundred and twenty-seven Chinese patients with NIDDM [15] who were not on lipid-lowering drugs and were regularly attending the Diabetes Clinic, Queen Mary Hospital, were studied. One hundred and sixty-eight normal control subjects [aged 37.2+ 10.4 years (mean±SD); 59 male and 109 female] were also recruited from among the hospital staff and their unrelated spouses. Subjects with intercurrent conditions and medications which may influence plasma apo(a) levels [16] [17] [18] [19] were excluded. All subjects gave informed consent and the protocol was approved by the Ethics Committee, Medical Faculty, The University of Hong Kong. All patients had two consecutive 12-h overnight urine collections for measurement of urinary albumin and creatinine and were classified into three groups according to the mean urinary albumin excretion rate (MAER): (1) no nephropathy or normoalbuminuria (MAER<20 ug/min; n=105); (2) incipient nephropathy or microalbuminuria (MAER 20-200 ug/min; n = 77); and (3) clinical nephropathy or albuminuria ( MAER > 200 ug/min; n=45). Clinical data, including smoking status, cardiovascular symptoms, body mass index (BMI), blood pressure (BP), fundoscopic finding by ophthalmoscopy (with pupils dilated to > 3 mm diameter), vibration perception threshold (for assessment of peripheral neuropathy), drug history, metabolic control and disease duration, were obtained from medical records. Smoking status was classified as non-smoker, smoker or ex-smoker (stopped smoking for >3 months). Ischaemic heart disease was diagnosed by a history of myocardial infarction, angina or evidence of myocardial infarction (pathological Q-wave) or significant horizontal ST segment depression (^2ram) in a resting 12-lead ECG. Macrovascular disease included ischaemic heart disease, stroke, transient ischaemic attack, or peripheral vascular disease as evidenced by intermittent claudication, rest pain, In all subjects, 10 ml EDTA blood was taken after fasting for 10-12 h for the measurement of HbAlc, total cholesterol, triglyceride, HDL-cholesterol and apo(a). Plasma albumin and creatinine were measured in heparinized blood. HbAlc was measured by electrophoresis using Beckman Paragon Diatric HbAlc Kits (Beckman Instruments, Brea, CA, USA). Total cholesterol and triglycerides were determined enzymatically (Boehringer Mannheim, Mannheim, Germany) on a Hitachi 717 analyser (Boehringer Mannheim). HDL-cholesterol was measured by the same method after precipitation of VLDL and LDL with PEG 6000. LDL-cholesterol was calculated according to the Friedewald equation. Apolipoproteins (apoAl and apoB) and urine albumin were measured by rate nephelometry using the Beckman Array System (Beckman Instruments). Plasma apo(a) was measured by an immunoradiometric assay (Pharmacia, Uppsala, Sweden), the intra-assay variations at low and high apo(a) levels being 2.6 and 1.4%, respectively; the corresponding inter-assay variations were 4.8 and 3.8%, respectively. Plasma and urine creatinine was measured by the Jaffe reaction [20] on a Hitachi 737 analyser (Boehringer Mannheim).
Apo(a) phenotyping was determined according to the method of Kamboh et al. [21] with minor modifications. Briefly, samples were prepared and adjusted for protein content by mixing 5-25 ul EDTA plasma with 35-55 |il reducing buffer and heating the mixture for 10 min at 100°C. Aliquots of 15 ul of the reduced samples were subjected to electrophoresis on a 1.5% agarose gel which contained a mixed apo(a) isoform standard (Immuno AG, Vienna, Austria) to control for gel-to-gel variation in electrophoresis conditions and to aid in differentiating closely migrating isoforms. After electrophoresis, proteins were transferred to a nylon membrane (Hybond-N, Amersham, UK). To reveal the apo(a) bands the membrane was immersed overnight in a monospecific, polyclonal sheep anti-human apo(a) antiserum (Immuno AG) and washed extensively before incubation with a second antibody, mouse anti-sheep IgG, conjugated with alkaline phosphatase (Immuno AG). The apo(a) banding pattern was visualized by chemiluminescent detection for alkaline phosphatase and exposure to X-ray films. Disodium 3-(4-methoxyspiro{l,2-dioxetane-3,2'-(5'-chloro)tricyclo[3.3.1.1 ]decan}-4-yl)phenyl phosphate (CSPD, Boehringer Mannheim) was used as the substrate solution.
Using the nomenclature proposed by Kraft et al. [22] , the various isoforms of apo(a) were designated according to their number of kringle IV (K-IV) repeats compared with those of the isoform standard. The standard contains five isoforms with 14, 19, 23, 27 and 35 K-IV repeats and was run alternately in each third or fourth lane as the reference. Sample isoforms were classified by comparison with the closest reference. The number of K-IV repeats of the apo(a) isoforms in the standard was determined by separation of Kpn\ restriction fragments of genomic DNA by pulsed field gel electrophoresis. In order to keep the conditions comparable with earlier published studies of apo(a) protein isoforms, the phenotypes were binned [23] according to the closest respective apo(a) isoforms [14] .
Statistical analysis
Statistical analysis was performed using the SPSS (version 4) statistics package. For continuous variables, Student's ttest was used for comparison between two groups and analysis of variance followed by Duncan's multiple range test was used for comparison of multiple groups. Because of their highly skewed distribution, log transformation of apo(a) values was carried out before analysis. Log transformation was also performed for serum creatinine and MAER because the values were not normally distributed. Categoric variables were compared using chi-square. Correlation between variables was tested using both univariate and multivariate analyses (Pearson's correlation analysis and multiple linear regression).
Results
As shown in Fig. 1 , there was no significant difference in apo(a) levels between controls (geometric mean 166 U/L; 95% confidence intervals 143, 193), normoalbuminuric patients (166; 137, 200) and microalbuminuric patients (162; 132, 209). Apo(a) levels in albuminuric patients (242; 184, 317) were however significantly higher (/ > <0.05) than in both controls and normoalbuminuric patients. The apo(a) phenotypes of controls and patients are shown in Table 1 . In only a small number of subjects was there no detectable apo(a) isoform, i.e. these were 'Null' phenotypes and associated with undetectable plasma apo(a). A single-band phenotype was found in 53.0, 62.9, 57.1 and 42.2% of 2231 controls, normoalbuminuric, microalbuminuric and albuminuric patients, respectively. In the remainder of the subjects two-band phenotypes were observed. The absence of a second band may result from homozygosity for one allele (rare) or if the second allele is not expressed or expressed at too low a level to be detectable. In Table 1 the smaller isoform expressed (i.e. that isoform which predominantly determined the plasma level) was used for classification of the phenotypes for comparisons between the four groups. The overall size range of apo(a) isoforms was similar among the four groups of subjects. The frequency of small isoforms corresponding to < 700 kDa was not significantly different among the four groups, being 13.1, 17.1, 13.0 and 13.3% for controls, normoalbuminuric, microalbuminuric and albuminuric patients, respectively. In all four groups, the most frequently found isoforms were those corresponding to 32-34 K-IV repeats. An inverse relationship was found between apo(a) size, expressed as the number of K-IV repeats for the smaller isoform, and log apo(a) levels in both controls (r =-0.709, P<0.001) and patients (r= -0.650, /><0.001).
Among the NIDDM patients (« = 227), there was no significant difference in apo(a) levels between patients with or without macrovascular disease, retinopathy or neuropathy. Using apo(a) ^ 300 U/L as a Controls Geometric Mean = 166 U/l n=168 cut-off level, a high apo(a) level was found in 33 and 28% of patients with and without macrovascular disease, respectively (/>=0.48). A positive correlation was found between log apo(a) and log plasma creatinine (r = 0.175, /><0.01). Not unexpectedly, log apo(a) correlated with LDL-cholesterol and apoB levels but showed no significant correlation with any other lipid parameters. There was no correlation between log apo(a) and HbAlc (r = 0.055), duration of diabetes (/-= 0.023), insulin dosage (/=-0.055), BMI 0 = 0.004), or log MAER (r = 0.123, /> = 0.068). In assessing other serum lipid and lipoprotein changes in patients with different stages of nephropathy, patients on p-blockers or thiazide were excluded from analysis. The clinical characteristics and biochemical findings of the remaining 209 NIDDM patients are summarized in Tables 2 and 3 , respectively. As shown in Table 2 , the prevalence of macrovascular disease was significantly increased in patients with microalbuminuria or albuminuria (P< 0.001 vs normoalbuminuric patients). When ischaemic heart disease alone was considered, the prevalence in patients with microalbuminuria was also higher compared to those with normoalbuminuria (P<0.05). A significant correlation with the presence of macrovascular disease was demonstrated for total cholesterol (r = 0.190, P<0.01), LDL-cholesterol (r = 0.241, P<0.001) and apoB levels (r = 0.301, /><0.001). Only apoB level was found to correlate significantly with the presence of ischaemic heart disease (r = 0.199, P<0.0\).
Both patients with microalbuminuria and albuminuria were older (P<0.01) than those with normoalbuminuria ( Table 2 ). Both groups also had greater BMI (P<0.05), longer duration of diabetes (/><0.05), higher systolic blood pressure (P<0.01) and higher prevalence of macrovascular disease (P<0.0\) compared to the group with normoalbuminuria. No significant difference in any of the other clinical characteristics was found between microalbuminuric and albuminuric patients.
Compared to normoalbuminuric patients, those with microalbuminuria and albuminuria (Table 3) had higher HbAlc, total cholesterol, triglyceride and apo B (P<0.0\ for both groups), higher LDL-cholesterol (P<0.05 and P<0.0\ for microalbuminuria and albuminuria, respectively) and lower HDL-cholesterol levels (P<0.01 and P<0.05, respectively). No significant difference in plasma lipids and lipoproteins was found between microalbuminuric and albuminuric patients. Both albuminuric and microalbuminuric patients had higher plasma creatinine levels compared to normoalbuminuric patients (P<0.0l); patients with albuminuria also had higher plasma creatinine levels than those with microalbuminuria (P<0.01). Using Pearson's univariate correlation analysis, it was found that a positive relationship existed between total cholesterol, LDL-cholesterol, apoB and HbAlc, age and duration of diabetes (Table 4) . Furthermore, BMI correlated positively with apoB and negatively with HDL-cholesterol, while log plasma creatinine correlated positively with total cholesterol, triglyceride and apoB. Although a significant correlation was demonstrated between log MAER and total cholesterol, triglyceride, HDL-cholesterol, LDL-cholesterol and apoB, it remained possible that the differences in HbAlc, age, duration and BMI among the three groups could produce an apparent difference in the mean values of plasma lipid levels between patients with different nephropathy staging (normoalbuminuria, microalbuminuria or albuminuria). To examine this possibility, multiple linear regressions were computed with each of the five plasma lipid fractions as the dependent variable, against all the covariates (including nephropathy staging, HbAlc, BMI, age and duration of diabetes). These established which covariates had a significant independent influence (P<0.05) on each of the five lipid fractions. The regressions were then recomputed using only the significant variables from the initial multiple regressions ( Table 5) . The results are given in Table 5 for analysis involving groups 1 (normoalbuminuria) and 2 (microalbuminuria) only, or involving all three groups (group 3, albuminuria). It was clear that the regression models are consistent between groups 1 and 2, as well as between groups 1, 2 and 3. It was also quite clear that in the multivariate situation, different nephropathy staging contributed significantly to the differences in lipid levels. Thus real, and not apparent, differences in mean lipid levels existed between the three groups of NIDDM patients with different nephropathy staging. Both microalbuminuria and albuminuria were independent predictors of total cholesterol, triglyceride, HDL-cholesterol and apoB levels. Apart from nephropathy staging, BMI was also predictive of low HDL-cholesterol and high apoB levels, and age was predictive of high apoB levels. Albuminuria, but not microalbuminuria, was predictive of increased LDLcholesterol levels, which were also predicted by the duration of diabetes.
Discussion
In this cross-sectional study on circulating apo (a) levels and phenotypes in Chinese patients with NIDDM, we have shown that plasma apo (a) levels and phenotypes in NIDDM patients, with or without microalbuminuria, were very similar to those of control subjects. On the other hand, patients with albuminuria had elevated apo (a) levels compared to normal controls and normoalbuminuric patients. We have also shown that the absence of a significant increase in apo (a) level in our NIDDM patients with microalbuminuria was unlikely to be a false negative finding because the frequency distribution of apo (a) isoforms was similar between patients with and without microalbuminuria. Our findings are in agreement with the general consensus that plasma apo(a) or Lp(a) is not increased in NIDDM, but becomes elevated in the presence of albuminuria [5, 7] . The positive correlation between log apo(a) and log plasma creatinine levels also corresponds to the negative correlation between apo(a) levels and creatinine clearance previously reported in patients with chronic renal failure following renal transplantation [24] and suggests that the regulation of Lp(a) metabolism can be affected by abnormal renal function of significant severity. Furthermore, the lack of a significant correlation between log apo (a) and log MAER in this study also suggests that the increase in Lp(a) levels in our patients with albuminuria, the majority of whom were far from nephrotic, was more likely to be related to their significantly reduced glomerular filtration rate, as inferred from their plasma creatinine levels. We were unable, however, to confirm in our 77 patients with mieroalbuminuria, the increase in apo (a) levels previously reported by Jenkins et al. [7] in 26 Australians with NIDDM and microalbuminuria, despite the use of similar methods in the measurement of microalbuminuria and apo (a) levels. This discrepancy might have arisen because of the much smaller patient sample size in the Australia study, which could have resulted in random deviations of apo (a) phenotypes leading to a false positive difference between the normoalbuminuric and microalbuminuric patients.
Whether ethnic differences in apo (a) genotype [25, 26] contribute to the conflicting findings on Lp(a) levels in NIDDM patients with microalbuminuria remains to be determined, although the mean apo (a) levels in our Chinese subjects did appear to be higher than those reported in the Australian study [7] . In a previous study plasma Lp(a) levels in Chinese were also found to be higher than those in Germans [26] . A recent study by Utermann's group in Austria, done in collaboration with our centre, has found that the higher Lp(a) levels in Chinese and Africans, compared to Caucasians, could not be solely explained by the differences in K-IV repeat allele frequencies among populations (H. G. Kraft et al., personal communication). On the other hand, recent studies conducted in North America (involving Mexican Americans and non-Hispanic white) [10] , Japan [9] , Denmark [12] and Austria [13] also showed no significant increase in apo (a) levels in NIDDM patients with microalbuminuria. In light of the findings from these recent studies and our own, it would appear that in NIDDM patients, the further enhancement in cardiovascular risk associated with the development of microalbuminuria cannot be attributed to changes in circulating Lp(a) levels. It is likely that the excess cardiovascular mortality and morbidity in NIDDM patients with microalbuminuria is related to the increased prevalence of other atherogenic risk factors. Higher systolic pressure [9, 11 ] and fibrinogen levels [9] in such patients have been reported. In this study, systolic blood pressure was also increased in the presence of microalbuminuria. Increased levels of von Willebrand factor, associated with other objective evidence of endothelial dysfunction, have been demonstrated in non-diabetic patients with microalbuminuria [27] and have been implicated as a link between nephropathy and atherosclerotic cardiovascular disease in NIDDM [28] . Adverse changes in circulating lipids and lipoproteins constitute another mechanism for enhanced atherogenesis in microalbuminuria. In Caucasians, NIDDM patients with persistent microalbuminuria have been shown, after a
